Full-Time

Sr. Manager

HCC Canada

Posted on 6/13/2026

Deadline 6/15/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Toronto, ON, Canada

Hybrid

Category
Legal & Compliance (2)
,
Required Skills
Risk Management
Requirements
  • Bachelor’s degree in Law, Business, Compliance, Finance, Healthcare Administration, or related field.
  • 8–10 years of progressive experience in healthcare compliance, legal, risk management, audit, or related fields.
  • Strong knowledge of healthcare compliance laws, regulations, and industry codes applicable in Canada.
  • Demonstrated leadership experience managing complex, country‑level compliance programs.
  • Proven ability to partner effectively with senior business leaders and cross‑functional stakeholders.
  • Strong analytical skills, sound judgment, and effective decision‑making and problem‑solving capabilities.
  • Excellent written and verbal communication skills, with the ability to influence without formal authority.
  • Ability to work independently while contributing effectively within a matrixed organization.
  • Travel up to 20–30%, primarily within Canada, with some regional travel.
  • Fluency in English is required; French proficiency is preferred.
  • Certifications: Compliance, legal, or ethics certifications are preferred but not required.
Responsibilities
  • Serve as the primary Healthcare Compliance Officer for Canada.
  • Lead the development and execution of healthcare compliance strategies aligned with global and regional (Latam/Canada) priorities.
  • Identify, assess, and manage compliance risks related to commercial, promotional, professional education, and other business and operational activities.
  • Provide proactive, practical guidance to business leaders on healthcare compliance requirements and ethical decision‑making.
  • Partner with cross‑functional stakeholders to embed effective compliance controls into business processes and go‑to‑market models.
  • Oversee compliance programs, including training, monitoring, risk assessments, and issue management activities across Canada.
  • Partner with Legal and other functions to support investigations, audits, and interactions with regulators or health authorities.
  • Monitor regulatory developments and industry trends in Canada to anticipate and address emerging compliance risks.
  • Prepare and present compliance risk assessments, insights, and recommendations to country, regional, and senior leadership.
  • Foster a strong culture of integrity, accountability, and speak‑up across the Canadian organization.
Desired Qualifications
  • Advanced degree or professional certification in Compliance, Legal, Risk, or Ethics‑related disciplines.
  • Experience in medical devices, pharmaceuticals, or the broader life sciences industry.
  • Prior experience supporting Canadian compliance programs within a global organization.
  • Familiarity with compliance monitoring, investigations, remediation, and audits.
  • Experience operating in highly matrixed, multicultural environments.
  • Strong change management and stakeholder‑influencing capabilities.
  • Certifications in compliance, legal, or ethics preferred but not required.
  • French proficiency (as a language skill) is preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Your Connections

People at Johnson & Johnson who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Firefly Bio expands J&J's KRAS-focused oncology platform for hard-to-treat tumors.
  • TREMFYA, CARVYKTI, and RYBREVANT are offsetting STELARA's biosimilar decline.
  • Jacksonville and Pennsylvania investments deepen manufacturing capacity and support future growth.

What critics are saying

  • STELARA's biosimilar erosion continues to pressure immunology revenue until replacements scale.
  • Talc litigation remains a recurring cash, reserve, and reputational overhang.
  • Firefly Bio's clinical-stage assets face efficacy risk before meaningful oncology contribution.

What makes Johnson & Johnson unique

  • J&J combines pharmaceuticals, MedTech, and consumer health across global markets.
  • Its 2026 pipeline spans oncology, immunology, neuroscience, and cardiovascular programs.
  • AAA credit and 64 straight dividend increases signal exceptional financial durability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE